Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-03: Torvutatug Samrotecan +/- Bevacizumab in Relapsed Ovarian Cancer
NCT07816666Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 13
01
Overview
A Phase 3 trial of torvutatug samrotecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Started Sep 2026; status: recruiting.
02
Drugs
torvutatug samrotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07816666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816666.